On May 22, 2023, Summit Therapeutics Inc. (NASDAQ: SMMT) opened at $1.67, lower -5.36% from the last session. During the day, the shares moved up to $1.72 and dropped to $1.57 before settling in for the closing price of $1.68. Price fluctuations for SMMT have ranged from $0.66 to $5.78 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -46.50% over the past five years. Company’s average yearly earnings per share was noted 57.60% at the time writing. With a float of $114.58 million, this company’s outstanding shares have now reached $193.34 million.
Let’s look at the performance matrix of the company that is accounted for 76 employees.
Summit Therapeutics Inc. (SMMT) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Summit Therapeutics Inc. is 90.80%, while institutional ownership is 1.70%. The most recent insider transaction that took place on Mar 08, was worth 16,772,430. In this transaction Co-Chief Executive Officer of this company bought 15,973,743 shares at a rate of $1.05, taking the stock ownership to the 23,395,269 shares. Before that another transaction happened on Mar 08, when Company’s Co-Chief Executive Officer bought 7,553,301 for $1.05, making the entire transaction worth $7,930,966. This insider now owns 9,884,095 shares in total.
Summit Therapeutics Inc. (SMMT) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/29/2021, the company posted -$1 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.29) by -$0.71. This company achieved a net margin of -6127.56 while generating a return on equity of -66.74. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 57.60% per share during the next fiscal year.
Summit Therapeutics Inc. (NASDAQ: SMMT) Trading Performance Indicators
Check out the current performance indicators for Summit Therapeutics Inc. (SMMT). In the past quarter, the stock posted a quick ratio of 16.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1528.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.63
Technical Analysis of Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (NASDAQ: SMMT) saw its 5-day average volume 1.6 million, a negative change from its year-to-date volume of 2.45 million. As of the previous 9 days, the stock’s Stochastic %D was 17.50%. Additionally, its Average True Range was 0.19.
During the past 100 days, Summit Therapeutics Inc.’s (SMMT) raw stochastic average was set at 7.51%, which indicates a significant decrease from 12.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 163.38% in the past 14 days, which was higher than the 140.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6570, while its 200-day Moving Average is $1.9444. Nevertheless, the first resistance level for the watch stands at $1.6833 in the near term. At $1.7767, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8333. If the price goes on to break the first support level at $1.5333, it is likely to go to the next support level at $1.4767. Assuming the price breaks the second support level, the third support level stands at $1.3833.
Summit Therapeutics Inc. (NASDAQ: SMMT) Key Stats
There are currently 697,685K shares outstanding in the company with a market cap of 1.07 billion. Presently, the company’s annual sales total 710 K according to its annual income of -78,780 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -19,230 K.
